CAFs have recently been shown to mediate MM proliferation and therapeutic resistance through the production of various cytokines (e.g., IL6, TGFβ), chemokines (e.g., SDF-1), and pro-inflammatory and pro-angiogenic factors (e.g., VEGF) [77,78]. The gene discussed is TGFB1; the disease is Miyoshi myopathy.